Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q6823893> ?p ?o }
Showing triples 1 to 41 of
41
with 100 triples per page.
- Q6823893 subject Q8255962.
- Q6823893 subject Q8421769.
- Q6823893 abstract "Methoxy polyethylene glycol-epoetin beta is the active ingredient of a drug marketed by Hoffmann-La Roche under the brand name Mircera. Mircera is a long-acting erythropoietin receptor activator (CERA) indicated for the treatment of patients with anaemia associated with chronic kidney disease. It is the first approved, chemically modified erythropoiesis-stimulating agent (ESA). Mircera is supplied as a solution in pre-filled syringes for intravenous or subcutaneous administration. Mircera was approved for use in Europe in July 2007 by the European Commission, in September 2007 by the Swissmedic, and in November 2007 by the U.S. Food and Drug Administration for use in the United States.Methoxy polyethylene glycol-epoetin beta is made from erythropoietin by chemically linking the N-terminal amino group or the Є-amino group of any lysine present in the protein with methoxy polyethylene glycol butanoic acid. The average molecular weight is approximately 60kDa. The drug stimulates erythropoiesis by interacting with the erythropoietin receptor on progenitor cells in the bone marrow.It has a different receptor binding activity to other ESAs and its reduced affinity for the erythropoietin receptor allows continuous stimulation. It has an in vivo half-life of around 135 hours as compared to darbapoietin alfa which has a half life of around 21 hours, the half life of which is three times that of the naturally occurring erthropoietin in the body.".
- Q6823893 atcPrefix "B03".
- Q6823893 atcSuffix "XA03".
- Q6823893 wikiPageWikiLink Q1363798.
- Q6823893 wikiPageWikiLink Q142.
- Q6823893 wikiPageWikiLink Q14852026.
- Q6823893 wikiPageWikiLink Q14904899.
- Q6823893 wikiPageWikiLink Q1641851.
- Q6823893 wikiPageWikiLink Q182854.
- Q6823893 wikiPageWikiLink Q204711.
- Q6823893 wikiPageWikiLink Q212646.
- Q6823893 wikiPageWikiLink Q2178381.
- Q6823893 wikiPageWikiLink Q30.
- Q6823893 wikiPageWikiLink Q33881.
- Q6823893 wikiPageWikiLink Q358263.
- Q6823893 wikiPageWikiLink Q470517.
- Q6823893 wikiPageWikiLink Q48663.
- Q6823893 wikiPageWikiLink Q496299.
- Q6823893 wikiPageWikiLink Q5445.
- Q6823893 wikiPageWikiLink Q546523.
- Q6823893 wikiPageWikiLink Q641855.
- Q6823893 wikiPageWikiLink Q6495575.
- Q6823893 wikiPageWikiLink Q681332.
- Q6823893 wikiPageWikiLink Q682252.
- Q6823893 wikiPageWikiLink Q7144498.
- Q6823893 wikiPageWikiLink Q749394.
- Q6823893 wikiPageWikiLink Q8255962.
- Q6823893 wikiPageWikiLink Q837174.
- Q6823893 wikiPageWikiLink Q8421769.
- Q6823893 wikiPageWikiLink Q886527.
- Q6823893 atcPrefix "B03".
- Q6823893 atcSuffix "XA03".
- Q6823893 type ChemicalSubstance.
- Q6823893 type Drug.
- Q6823893 type ChemicalObject.
- Q6823893 type Thing.
- Q6823893 type Q8386.
- Q6823893 comment "Methoxy polyethylene glycol-epoetin beta is the active ingredient of a drug marketed by Hoffmann-La Roche under the brand name Mircera. Mircera is a long-acting erythropoietin receptor activator (CERA) indicated for the treatment of patients with anaemia associated with chronic kidney disease. It is the first approved, chemically modified erythropoiesis-stimulating agent (ESA). Mircera is supplied as a solution in pre-filled syringes for intravenous or subcutaneous administration.".
- Q6823893 label "Methoxy polyethylene glycol-epoetin beta".